Home > Dermatology > EADV 2022 > Selective IL-23 inhibitor shows long-term efficacy in active PsA

Selective IL-23 inhibitor shows long-term efficacy in active PsA

Presented By
Prof. Kim Papp, Probity Medical Research, Canada
Conference
EADV 2022
Trial
Phase 3, KEEPsAKE 1/2
The 100-week results of the KEEPsAKE 1 and 2 trials demonstrated high efficacy of the IL-23 blocker risankizumab in adult patients with active psoriatic arthritis (PsA), independent of previous therapy. Risankizumab showed an excellent safety profile with no new safety signals or unanticipated adverse events. The phase 3 programme KEEPsAKE was established to assess the efficacy of risankizumab in psoriatic arthritis. “We already know that it has an important effect on cutaneous manifestations,” Prof. Kim Papp (Probity Medical Research, Canada) said during the presentation of the 100-week results of the trial programme [1]. The (positive) 24-week results of the double-blind study period were already presented previously [2,3]. At this time, all patients entered an open-label extension period and placebo patients were switched to risankizumab 150 mg every 12 weeks. In both the KEEPsAKE 1 (


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on